Medilumine is pleased to announce a new distribution partnership with NanoPET Pharma through its Viscover brand. Medilumine is now an authorized distributor of the full Viscover platform for in vivo preclinical imaging including:
MicroCT Contrast Agents
MRI Contrast Agents
Fluorescent Contrast Agents
Ultrasound Contrast Agents
This partnership expands access to well established contrast agents that support detailed soft tissue and vascular imaging beyond conventional skeletal CT.
Viscover ExiTron agents are widely used in preclinical research to enable high contrast visualization of vascular networks, organs, and disease related changes in tissue perfusion and structure. Their nanoparticle based formulation allows for prolonged circulation and uptake in target tissues, making them suitable for applications such as angiography, organ perfusion studies, tumor vascularization analysis, and longitudinal imaging in small animal models.
Through this partnership, Medilumine provides direct and authorized access to NanoPET Pharma reagents along with scientific and application level support. Researchers can obtain guidance on selecting appropriate contrast agents for their animal models and imaging platforms, including integration into multimodal workflows that combine micro CT with optical, fluorescence, or other imaging techniques. Medilumine also offers a reliable supply chain and transparent ordering process to support reproducible and time sensitive studies.
The ExiTron product family includes agents optimized for different biological and imaging needs. ExiTron nano 12000 is designed for high resolution vascular imaging and liver tumor detection, enabling detailed visualization of blood vessels and pathological neovascularization. ExiTron nano 6000 provides liver specific uptake and is suitable for longitudinal organ imaging where stable contrast over time is required. Additional ExiTron variants are available to support diverse preclinical applications across oncology, cardiovascular research, inflammation, and organ function studies.
By combining Viscover contrast agents with Medilumine’s expertise in preclinical imaging workflows, researchers gain access to both validated reagents and technical support that facilitates quantitative and reproducible micro CT studies. This partnership is intended to streamline the process of reagent selection, experimental design, and imaging execution for laboratories working in translational and discovery research.
MRI Imaging
Medilumine offers the Viscover™ portfolio of preclinical MRI contrast agents, designed to enhance image quality and expand the capabilities of animal MRI studies. The portfolio includes GadoSpin™ gadolinium chelates for high-performance vascular, organ, and tumor imaging, and FeraSpin™ iron oxide nanoparticles, which are widely used for cell labeling and in vivo cell tracking by MRI. Together, Viscover MRI agents support applications such as cell tracking, tumor and vascular imaging, cardiovascular studies, magnetic resonance angiography (MRA), and therapy response monitoring, enabling more informative and translational preclinical imaging.
For further information on ExiTron products, technical documentation, or assistance in selecting the most appropriate contrast agent for your study, please contact the Medilumine team.
Medilumine is pleased to announce a new distribution partnership with NanoPET Pharma through its Viscover brand. Medilumine is now an authorized distributor of the full
Recent preclinical research by the laboratory of Dr. Hisataka Kobayashi (Director of Molecular Theranostics, NIH) explored the potential of carbonic anhydrase‑9 (CA9) as a theranostic
